Spyre Therapeutics, Inc. (NASDAQ: SYRE) reported Q1 EPS of ($0.60), $0.24 better than the analyst estimate of ($0.84).

For earnings history and earnings-related data on Spyre Therapeutics, Inc. (SYRE) click here.